In this study, semaglutide (a long-acting GLP-1R agonist) showed an unexpectedly higher rate of severe DR complications (i.e., vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation).71 This evidence concerns the gene GLP1R and Blindness.